| Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19 J Sadoff, G Gray, A Vandebosch, V Cárdenas, G Shukarev, B Grinsztejn, ... New England Journal of Medicine 384 (23), 2187-2201, 2021 | 2525 | 2021 |
| Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a … J Paavonen, P Naud, J Salmerón, CM Wheeler, SN Chow, D Apter, ... The Lancet 374 (9686), 301-314, 2009 | 2054 | 2009 |
| Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of … J Paavonen, D Jenkins, FX Bosch, P Naud, J Salmerón, CM Wheeler, ... The Lancet 369 (9580), 2161-2170, 2007 | 1678 | 2007 |
| A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women EA Joura, AR Giuliano, OE Iversen, C Bouchard, C Mao, J Mehlsen, ... New England Journal of Medicine 372 (8), 711-723, 2015 | 1631 | 2015 |
| Interim results of a phase 1–2a trial of Ad26. COV2. S Covid-19 vaccine J Sadoff, M Le Gars, G Shukarev, D Heerwegh, C Truyers, AM de Groot, ... New England Journal of Medicine 384 (19), 1824-1835, 2021 | 1224 | 2021 |
| Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double … M Lehtinen, J Paavonen, CM Wheeler, U Jaisamrarn, SM Garland, ... The lancet oncology 13 (1), 89-99, 2012 | 890 | 2012 |
| Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis … CM Wheeler, X Castellsagué, SM Garland, A Szarewski, J Paavonen, ... The lancet oncology 13 (1), 100-110, 2012 | 619 | 2012 |
| Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials AR Kreimer, F Struyf, MR Del Rosario-Raymundo, A Hildesheim, ... The lancet oncology 16 (7), 775-786, 2015 | 349 | 2015 |
| Immunogenicity of Ad26. COV2. S vaccine against SARS-CoV-2 variants in humans G Alter, J Yu, J Liu, A Chandrashekar, EN Borducchi, LH Tostanoski, ... Nature 596 (7871), 268-272, 2021 | 324 | 2021 |
| Immunogenicity of the Ad26. COV2. S Vaccine for COVID-19 KE Stephenson, M Le Gars, J Sadoff, AM de Groot, D Heerwegh, ... Jama 325 (15), 1535-1544, 2021 | 321 | 2021 |
| Durable humoral and cellular immune responses 8 months after Ad26. COV2. S vaccination DH Barouch, KE Stephenson, J Sadoff, J Yu, A Chang, M Gebre, ... New England Journal of Medicine 385 (10), 951-953, 2021 | 242 | 2021 |
| One virus, one lesion—individual components of CIN lesions contain a specific HPV type W Quint, D Jenkins, A Molijn, L Struijk, M van de Sandt, J Doorbar, J Mols, ... The Journal of pathology 227 (1), 62-71, 2012 | 221 | 2012 |
| Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double … SR Skinner, A Szarewski, B Romanowski, SM Garland, E Lazcano-Ponce, ... The Lancet 384 (9961), 2213-2227, 2014 | 215 | 2014 |
| Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind … CM Wheeler, SR Skinner, MR Del Rosario-Raymundo, SM Garland, ... The Lancet Infectious Diseases 16 (10), 1154-1168, 2016 | 211 | 2016 |
| Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study U Jaisamrarn, X Castellsague, SM Garland, P Naud, J Palmroth, ... PloS one 8 (11), e79260, 2013 | 199 | 2013 |
| Final analysis of efficacy and safety of single-dose Ad26. COV2. S J Sadoff, G Gray, A Vandebosch, V Cárdenas, G Shukarev, B Grinsztejn, ... New England Journal of Medicine 386 (9), 847-860, 2022 | 187 | 2022 |
| Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV‐16/18 A Szarewski, WAJ Poppe, SR Skinner, CM Wheeler, J Paavonen, P Naud, ... International journal of cancer 131 (1), 106-116, 2012 | 175 | 2012 |
| Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study S Rachel Skinner, CM Wheeler, B Romanowski, X Castellsagué, ... International journal of cancer 138 (10), 2428-2438, 2016 | 164 | 2016 |
| Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial ER Bahmanyar, J Paavonen, P Naud, J Salmerón, SN Chow, D Apter, ... Gynecologic oncology 127 (3), 440-450, 2012 | 136 | 2012 |
| Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post‐hoc … SM Garland, J Paavonen, U Jaisamrarn, P Naud, J Salmerón, SN Chow, ... International journal of cancer 139 (12), 2812-2826, 2016 | 133 | 2016 |
